Lapatinib

Form: Tablet

Strength: 250 mg, 500 mg

Reference Brands: Tykerb® (EU & US)

Category: Oncology Cancer Care

Lapatinib is a targeted cancer therapy used in the treatment of HER2-positive breast cancer. As a tyrosine kinase inhibitor (TKI), it inhibits the HER2 receptor, a key driver of cancer cell growth. Available in 250 mg and 500 mg oral tablets, Lapatinib is marketed under the brand name Tykerb® by GlaxoSmithKline and is also available in generic forms. Widely sourced by B2B pharmaceutical wholesalers in the US and EU, Lapatinib ensures reliable supply for oncology clinics and cancer centers. Its GMP-compliant distribution offers competitive pricing, making it a key player in breast cancer treatment.